Panacea Index Logo

Command Palette

Search for a command to run...

Calcium pyrophosphate deposition (CPPD) in a liver transplant patient: are hypomagnesemia, tacrolimus or both guilty? A case-based literature review.

Rheumatology international
June 1, 2022
Simon Cadiou et al. (8 authors)
Case ReportsJournal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to investigate the link between persistent hypomagnesemia induced by tacrolimus and calcium pyrophosphate deposition (CPPD) in a liver transplant patient.

Results Summary

The study found that hypomagnesemia caused by tacrolimus led to CPPD, presenting as acute oligoarthritis and low back pain. After switching to everolimus and supplementing magnesium, the patient's symptoms resolved without relapse over 8 months.

Population

A 53-year-old male liver transplant recipient.

Effective Dosage

Not specified

Duration

8 months follow-up

Interactions

Tacrolimus (renal magnesium loss), proton pump inhibitor (potential contributor to hypomagnesemia)

Extracted Claims (5)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Persistent hypomagnesemia
increase
Calcium pyrophosphate deposition (CPPD)
-
-
can be induced by
#1
Tacrolimus
increase
hypomagnesemia
organ transplant patient
-
potentially inducer of
#2
Tacrolimus
increase
renal loss
-
-
induces hypomagnesemia by
#3
Magnesium oral supplementation
neutral
-
53-year-old man, liver transplant 10 months earlier
-
was started
#4
Magnesium oral supplementation
no change
no relapse of pain
53-year-old man, liver transplant 10 months earlier
-
resulted in
#5
Abstract

Calcium pyrophosphate deposition (CPPD) can be induced by a persistent hypomagnesemia. Tacrolimus is an immunosuppressive treatment especially used in organ transplant, potentially inducer of hypomagnesemia by renal loss. A 53-year-old man, liver transplant 10 months earlier, developed an acute peripheral oligoarthritis of wrist, hip and elbow with fever, associated with acute low back pain. Synovial fluid was sterile, and revealed calcium pyrophosphate crystals. Spinal imaging showed inflammatory changes. Magnesium blood level was low at 0.51 mmol/l, with high fractional excretion in favor of renal loss. Tacrolimus was changed for everolimus, proton pump inhibitor was stopped, and magnesium oral supplementation was started. After 8 months follow-up and slow prednisone tapering, he did not relapse pain. Persistent hypomagnesemia is a rare secondary cause of CPPD. In this entity, drug liability should be investigated such as tacrolimus in organ transplant patient.

Medical Subject Headings (MeSH)
CalcinosisCalcium PyrophosphateChondrocalcinosisHumansLiver TransplantationMagnesiumMaleMiddle AgedSynovial FluidTacrolimus
Study Links
Quality Scores
SafetyNot Assessed
Efficacy30/10
Quality40/10
0
Research Impact Scores
APT Score0.05
Weight Score1.64
Normalized Score0.40
Related Supplements
Calcium pyrophosphate deposition (CPPD) in a liver transplan... | Panacea Index